487 related articles for article (PubMed ID: 31801559)
1. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Fang Y; Liao G; Yu B
J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
[TBL] [Abstract][Full Text] [Related]
2. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
3. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
4. Advances toward LSD1 inhibitors for cancer therapy.
Fu X; Zhang P; Yu B
Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
[TBL] [Abstract][Full Text] [Related]
5. Recent advances of LSD1/KDM1A inhibitors for disease therapy.
Zhang C; Wang Z; Shi Y; Yu B; Song Y
Bioorg Chem; 2023 May; 134():106443. PubMed ID: 36857932
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM
J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982
[TBL] [Abstract][Full Text] [Related]
7. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
8. LSD1: biologic roles and therapeutic targeting.
Maiques-Diaz A; Somervaille TC
Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
10. What potential is there for LSD1 inhibitors to reach approval for AML?
Pandey MR; Wang ES
Expert Opin Emerg Drugs; 2019 Dec; 24(4):205-212. PubMed ID: 31914875
[No Abstract] [Full Text] [Related]
11. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Inhibition of LSD1 for Cancer Treatment.
Yang GJ; Lei PM; Wong SY; Ma DL; Leung CH
Molecules; 2018 Dec; 23(12):. PubMed ID: 30518104
[TBL] [Abstract][Full Text] [Related]
14. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
Stewart CA; Byers LA
Cancer Cell; 2015 Jul; 28(1):4-6. PubMed ID: 26175409
[TBL] [Abstract][Full Text] [Related]
15. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
[TBL] [Abstract][Full Text] [Related]
16. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Maes T; Mascaró C; Tirapu I; Estiarte A; Ciceri F; Lunardi S; Guibourt N; Perdones A; Lufino MMP; Somervaille TCP; Wiseman DH; Duy C; Melnick A; Willekens C; Ortega A; Martinell M; Valls N; Kurz G; Fyfe M; Castro-Palomino JC; Buesa C
Cancer Cell; 2018 Mar; 33(3):495-511.e12. PubMed ID: 29502954
[TBL] [Abstract][Full Text] [Related]
17. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
[TBL] [Abstract][Full Text] [Related]
18. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
19. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Noce B; Di Bello E; Fioravanti R; Mai A
Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147
[TBL] [Abstract][Full Text] [Related]
20. Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
Xu S; Zhou C; Liu R; Zhu Q; Xu Y; Lan F; Zha X
Bioorg Med Chem; 2018 Sep; 26(17):4871-4880. PubMed ID: 30153955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
